2. Search Result
Search Result
Results for "

acute monocytic leukemia

" in MedChemExpress (MCE) Product Catalog:

14

Inhibitors & Agonists

1

Biochemical Assay Reagents

1

Peptides

1

Inhibitory Antibodies

1

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-168654
    WEE1 degrader 1

    		Wee1 Cancer
    WEE1 degrader 1 (Compound 10) is a CRBN-dependent molecular glue degrader of WEE1 and casein kinase 1α (CK1α) with sub-2 nM DC50 values for both targets. WEE1 degrader 1 can be used for the research of acute lymphoblastic leukemia, acute monocytic leukemia, acute promyelocytic leukemia, colorectal adenocarcinoma, diffuse large b cell lymphoma .
    WEE1 degrader 1
  • HY-155175
    TIM-3-IN-2

    		Tim3 IFNAR Cancer
    TIM-3-IN-2 is a TIM-3 inhibitor. TIM-3-IN-2 blocks the interactions of TIM-3 with PtdSer, CEACAM1 and Gal-9, and inhibits the immunosuppressive function of TIM-3. TIM-3-IN-2 restores IFNγ release from peripheral blood mononuclear cells. TIM-3-IN-2 inhibits the proliferation of acute myeloid leukemia cells. TIM-3-IN-2 can be used for the research of acute myeloid leukemia .
    TIM-3-IN-2
  • HY-141539
    SETDB1-TTD-IN-1
    5 Publications Verification

    		 Histone Methyltransferase Akt Cancer
    SETDB1-TTD-IN-1 is a SETDB1 methyltransferase activator and SETDB1-TTD competitive inhibitor (Kd of 88 nM), and selectivity for SETDB1-TTD over other tudor and bromodomain proteins. SETDB1-TTD-IN-1 stimulates methyltransferase activity via increased catalytic activity, promotes Akt1 Lys64 methylation, Akt1 Thr308 phosphorylation and activation. SETDB1-TTD-IN-1 prevents SETDB1-TTD-histone H3 peptide association, induces global gene expression changes, exhibits cellular target engagement, and acts as a tool compound for SETDB1-TTD function exploration. SETDB1-TTD-IN-1 can be used for the research of breast cancer .
    SETDB1-TTD-IN-1
  • HY-139410
    Sodium caseinates

    		c-Fms Inflammation/Immunology
    Sodium caseinates is a kind of sodium salts of major milk proteins, which act as protein-based biopolymers and innate immune system activators. Sodium caseinates induce granulopoiesis, activation and differentiation, promote the production of M-CSF, and increase serum levels of G-CSF and GM-CSF. Sodium caseinates inhibit the proliferation and reduce the viability of leukemia macrophage-like cells, thereby significantly improving the survival rate of mice inoculated with leukemia cells. Sodium caseinates can serve as carriers for probiotics in edible films and exhibit anti-Listeria activity. Sodium caseinates effectively protect vitamin A from degradation, enhance its stability, bioaccessibility and bioavailability, and regulate protein digestibility when complexed with vitamin A. Sodium caseinates can be applied to research related to acute monocytic leukemia and vitamin A deficiency .
    Sodium caseinates
  • HY-162608
    PROTAC JAK1 degrader 1

    		PROTACs JAK STAT Cancer
    PROTAC JAK1 degrader 1 is a JAK1 PROTAC degrader with a DC50 of 214 nM and an IC50 of 5.2 nM. PROTAC JAK1 degrader 1 inhibits the downstream JAK-STAT signaling pathway by degrading JAK1. PROTAC JAK1 degrader 1 exhibits antiproliferative activity in cells. PROTAC JAK1 degrader 1 can be used for research on leukemia .
    PROTAC JAK1 degrader 1
  • HY-P4122
    TAT (47-57), FAM-labeled

    		HIV Others
    TAT (47-57), FAM-labeled is a 5(6)-Carboxyfluorescein (HY-15940)-labeled TAT (HY-P0281). TAT (YGRKKRRQRRR) is derived from the transactivator of transcription (TAT) of human immunodeficiency virus-1 (HIV-1) and is a cell-penetrating peptide .
    TAT (47-57), FAM-labeled
  • HY-N8390
    3-Epidehydropachymic acid

    		Others Cancer
    3-Epidehydropachymic acid, a lanostane triterpenoid, shows totoxicity effect against human acute monocytic leukemia cell line THP-1 (IC50=52.51 μM) .
    3-Epidehydropachymic acid
  • HY-147609
    CSF1R-IN-8

    		c-Fms Cancer
    CSF1R-IN-8 (Compound 22) is a CSF-1R inhibitor with an IC50 of 0.012 μM .
    CSF1R-IN-8
  • HY-147611
    CSF1R-IN-10

    		c-Fms Cancer
    CSF1R-IN-10 (Compound 48) is a CSF-1R inhibitor with an IC50 of 0.005 μM .
    CSF1R-IN-10
  • HY-76293
    I2906
    1 Publications Verification

    		 Bacterial Infection
    I2906 is an orally active isocitrate lyase (ICL) inhibitor with a Mycobacterium tuberculosis IC50 of 134.3 μg/mL. I2906 inhibits the growth of Mycobacterium tuberculosis. I2906 can be used for the research of tuberculosis .
    I2906
  • HY-147610
    CSF1R-IN-9

    		c-Fms Cancer
    CSF1R-IN-9 (Compound 46) is a CSF-1R inhibitor with an IC50 of 0.028 μM .
    CSF1R-IN-9
  • HY-181048
    CK1α-IN-1

    		Casein Kinase MDM-2/p53 Cancer
    CK1α-IN-1 (Compound 7a) is a selective CK1α inhibitor with an IC50 of 10.96 nM. CK1α-IN-1 dose-dependently stabilizes p53 protein. CK1α-IN-1 has anticancer activity against acute monocytic leukemia .
    CK1α-IN-1
  • HY-P992389
    IO-202

    		LILRB Cancer
    IO-202 is a high-affinity LILRB4/ILT3 binder and myeloid checkpoint inhibitor. IO-202 blocks APOE binding and LILRB4 activation to reverse T-cell suppression and enhance T-cell cytotoxicity, while eliminating LILRB4-high-expressing leukemic blasts via ADCC and ADCP mechanisms. IO-202 promotes dendritic cell maturation and antigen presentation, reshapes the phenotype of tumor-associated macrophages, and reduces myeloid-derived suppressor cells. IO-202 is widely applicable to research on relapsed/refractory acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and solid tumors .
    IO-202
  • HY-W207224
    F1386-0303

    		MAP4K Cardiovascular Disease Inflammation/Immunology
    F1386-0303 is a highly selective MAP4K4 inhibitor with an IC50 of 34 nM against human targets. F1386-0303 exerts cardiomyocyte protective and function-preserving effects through mechanisms such as alleviating oxidative stress, inhibiting caspases, and maintaining mitochondrial membrane potential, while it does not interfere with the activity of Doxorubicin (HY-15142A) in cancer cells. F1386-0303 is rapidly cleared and has no bioavailability in mice, but it is well-suited as a tool compound for target validation. F1386-0303 can be applied to studies related to cardiac ischemia-reperfusion injury, Doxorubicin-induced cardiotoxicity, myocardial infarction and other related conditions .
    F1386-0303

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: